By harnessing these cells' inherent cytotoxic mechanisms and incorporating CAR technology, common CAR-T cell-related limitations can be effectively mitigated. We herein present an overview of the tumoricidal mechanisms, CAR designs, and manufacturing processes of CAR-NK cells, CAR-MΦ, CAR-iNKT ...
[Abstract]Background and purpose:Chimeric antigen receptor T (CAR-T) cell technology has been widely used in the field of blood tumor treatment. Lentivirus transduction is a key link in the preparation of CAR-T cells, which is ...
Chimaeric antigen receptor (CAR) T cells can generate durable clinical responses in B-cell haematologic malignancies. The manufacturing of these T cells typically involves their activation, followed by viral transduction and expansion ex vivo for at leas
The SNIP-CARs technology, a protease-regulated platform, utilizes small-molecule drugs such as grazoprevir to modulate the activity of CAR-T cells. This strategy maintains CAR-T cells in an inactive state until they are reactivated by a drug, indicating its potential as a therapeutic safety ...
Chimeric antigen receptor T cells (CAR T cells) are effective against haematologic malignancies. However, in solid tumours, their potency is hampered by local immunosuppression and by the heterogeneous expression of the antigen that the CAR targets. Here
CAR Animal Cells Stable Cell LinePlatforms CellRapeutics™ CAR Technology CellRapeutics™ TCR Technology CAR × TCR Bispecific T Cell Engineering Platform Surfarray™ Cell Microarray Technology T-Scan Platform for T Cell-Specific Epitope Identification Animal Model Platform for CAR-T Therapeutic Re...
Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved remarkable success in some hematological malignancies in preclinical and clinical trials, resulting in
CAR-T cells are generated by the T cells from patients’ or donors’ blood. After the T cells are expanded and genetically modified, they are reinfused into the patients. However, many challenges still need to be resolved in order for this technology to gain widespread adoption. In this ...
Opportunity:New technology for improving therapy efficiency Multiple myeloma therapy options are limited, although CAR T-cells, modified T cells with lymphocyte-like signaling molecules, have shown promise in targeting genes in malignant cells. Clinical trials are curren...
blood. After the T cells are expanded and genetically modified, they are reinfused into the patients. However, many challenges still need to be resolved in order for this technology to gain widespread adoption. In this review, we first discuss the structure and evolution of chimeric antigen rece...